Foundry Healthcare Gross Profitability Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1LLY | ELI LILLY & CO | Healthcare | $1.11T | 67.98% |
2HCA | HCA HEALTHCARE INC | Healthcare | $82.34B | 5.04% |
3IDXX | IDEXX LABORATORIES INC | Healthcare | $44.76B | 2.74% |
4NTRA | NATERA INC | Healthcare | $38.87B | 2.38% |
5ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $35.71B | 2.19% |
6ONC | BEONE MEDICINES LTD | Healthcare | $34.68B | 2.12% |
7MTD | METTLER TOLEDO INTERNATIONAL INC | Healthcare | $26.47B | 1.62% |
8INCY | INCYTE CORP | Healthcare | $23.42B | 1.43% |
9NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.18B | 1.05% |
10THC | TENET HEALTHCARE CORP | Healthcare | $16.79B | 1.03% |
11EXEL | EXELIXIS INC | Healthcare | $14.06B | 0.86% |
12MDGL | MADRIGAL PHARMACEUTICALS INC | Healthcare | $12.76B | 0.78% |
13PEN | PENUMBRA INC | Healthcare | $12.52B | 0.77% |
14AXSM | AXSOME THERAPEUTICS INC | Healthcare | $11.84B | 0.72% |
15PODD | INSULET CORP | Healthcare | $11.36B | 0.70% |
16CORT | CORCEPT THERAPEUTICS INC | Healthcare | $9.72B | 0.59% |
17UHS | UNIVERSAL HEALTH SERVICES INC | Healthcare | $9.15B | 0.56% |
18MIRM | MIRUM PHARMACEUTICALS INC | Healthcare | $7.25B | 0.44% |
19LQDA | LIQUIDIA CORP | Healthcare | $7.11B | 0.44% |
20CHE | CHEMED CORP | Healthcare | $6.77B | 0.41% |
21HNGE | HINGE HEALTH INC | Healthcare | $6.74B | 0.41% |
22TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $5.27B | 0.32% |
23KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $4.92B | 0.30% |
24CAI | CARIS LIFE SCIENCES INC | Healthcare | $4.66B | 0.29% |
25ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $4.38B | 0.27% |
26DOCS | DOXIMITY INC | Healthcare | $3.94B | 0.24% |
27IRTC | IRHYTHM HOLDINGS INC | Healthcare | $3.64B | 0.22% |
28NHC | NATIONAL HEALTHCARE CORP | Healthcare | $3.56B | 0.22% |
29ARQT | ARCUTIS BIOTHERAPEUTICS INC | Healthcare | $3.56B | 0.22% |
30WRBY | WARBY PARKER INC | Healthcare | $3.24B | 0.20% |
31TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $2.58B | 0.16% |
32GRDN | GUARDIAN PHARMACY SERVICES INC | Healthcare | $2.57B | 0.16% |
33BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $2.36B | 0.14% |
34AXGN | AXOGEN INC | Healthcare | $2.12B | 0.13% |
35CDNA | CAREDX INC | Healthcare | $2.05B | 0.13% |
36URGN | UROGEN PHARMA LTD | Healthcare | $1.96B | 0.12% |
37HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.96B | 0.12% |
38WGS | GENEDX HOLDINGS CORP | Healthcare | $1.88B | 0.12% |
39NVCR | NOVOCURE LTD | Healthcare | $1.84B | 0.11% |
40ATRC | ATRICURE INC | Healthcare | $1.77B | 0.11% |
41HROW | HARROW INC | Healthcare | $1.74B | 0.11% |
42TDOC | TELADOC HEALTH INC | Healthcare | $1.70B | 0.10% |
43ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.10% |
44XERS | XERIS BIOPHARMA HOLDINGS INC | Healthcare | $1.52B | 0.09% |
45INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.46B | 0.09% |
46OMDA | OMADA HEALTH INC | Healthcare | $1.41B | 0.09% |
47NVAX | NOVAVAX INC | Healthcare | $1.35B | 0.08% |
48STAA | STAAR SURGICAL CO | Healthcare | $1.32B | 0.08% |
49ATEC | ALPHATEC HOLDINGS INC | Healthcare | $1.31B | 0.08% |
50ARDX | ARDELYX INC | Healthcare | $1.28B | 0.08% |
51IRMD | IRADIMED CORP | Healthcare | $1.24B | 0.08% |
52TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.17B | 0.07% |
53ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.16B | 0.07% |
54PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.01B | 0.06% |
55BVS | BIOVENTUS INC | Healthcare | $1.01B | 0.06% |
56TALK | TALKSPACE INC | Healthcare | $873M | 0.05% |
57PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $873M | 0.05% |
58SIBN | SI-BONE INC | Healthcare | $771M | 0.05% |
59RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $750M | 0.05% |
60CSTL | CASTLE BIOSCIENCES INC | Healthcare | $733M | 0.04% |
61PHR | PHREESIA INC | Healthcare | $662M | 0.04% |
62TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $648M | 0.04% |
63GYRE | GYRE THERAPEUTICS INC | Healthcare | $587M | 0.04% |
64MYGN | MYRIAD GENETICS INC | Healthcare | $584M | 0.04% |
65WEAV | WEAVE COMMUNICATIONS INC | Healthcare | $575M | 0.04% |
66ANGO | ANGIODYNAMICS INC | Healthcare | $558M | 0.03% |
67NPCE | NEUROPACE INC | Healthcare | $548M | 0.03% |
68TOI | ONCOLOGY INSTITUTE INC | Healthcare | $535M | 0.03% |
69NRC | NRC HEALTH | Healthcare | $491M | 0.03% |
70OFIX | ORTHOFIX MEDICAL INC | Healthcare | $468M | 0.03% |
71VMD | VIEMED HEALTHCARE INC | Healthcare | $466M | 0.03% |
72DCTH | DELCATH SYSTEMS INC | Healthcare | $442M | 0.03% |
73PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.03% |
74EOLS | EVOLUS INC | Healthcare | $377M | 0.02% |
75FENC | FENNEC PHARMACEUTICALS INC | Healthcare | $365M | 0.02% |
76ELMD | ELECTROMED INC | Healthcare | $349M | 0.02% |
77SGHT | SIGHT SCIENCES INC | Healthcare | $274M | 0.02% |
78QTTB | Q32 BIO INC | Healthcare | $255M | 0.02% |
79SMTI | SANARA MEDTECH INC | Healthcare | $229M | 0.01% |
80SPOK | SPOK HOLDINGS INC | Healthcare | $222M | 0.01% |
81KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.01% |
82AGEN | AGENUS INC | Healthcare | $209M | 0.01% |
83BDSX | BIODESIX INC | Healthcare | $204M | 0.01% |
84INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $180M | 0.01% |
85INGN | INOGEN INC | Healthcare | $178M | 0.01% |
86OWLT | OWLET INC | Healthcare | $162M | 0.01% |
87RCEL | AVITA MEDICAL INC | Healthcare | $157M | 0.01% |
88CUE | CUE BIOPHARMA INC | Healthcare | $126M | 0.01% |
89CPIX | CUMBERLAND PHARMACEUTICALS INC | Healthcare | $103M | 0.01% |
90VRCA | VERRICA PHARMACEUTICALS INC | Healthcare | $96M | 0.01% |
91CSBR | CHAMPIONS ONCOLOGY INC | Healthcare | $85M | 0.01% |
92ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $76M | 0.00% |
93SNWV | SANUWAVE HEALTH INC | Healthcare | $55M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $1.63T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 98% toward Large, 89% toward Growth. +2% unclassified (17 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 93 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual37.0%Margin-38.0%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual68.0%Margin-43.0%
At least 50% of total assets must sit in cash, government securities, other RICs, and other securities limited to 5% of assets and 10% of the issuer's voting securities per issuer.
Required>= 50.0%Actual37.0%Margin-13.0%Arithmetically entailed by '40 Act 5(b)(1) diversification (75%/5% asset leg) — it cannot fail independently, so it is reported outside the tally rather than counted as a separate check.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 93 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 33%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 32.8% | -37.3% |
| 3 yearsp.a. | 19.6% | -9.4% |
| 5 yearsp.a. | 12.3% | 3.4% |
| 10 yearsp.a. | 12.4% | -1.3% |
| Since inceptionp.a. | 9.4% | -1.1% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 10.6% | -22.7% |
| 2025 | 18.8% | -10.1% |
| 2024 | 20.1% | 12.8% |
| 2023 | 22.5% | -4.2% |
| 2022 | -6.9% | 22.1% |
| 2021 | 14.2% | 88.1% |
| 2020 | 19.9% | -16.6% |
| 2019 | 20.6% | -32.3% |
| 2018 | -1.3% | 26.1% |
| 2017 | 17.9% | -27.7% |
| 2016 | -11.2% | 13.5% |
| 2015 | 6.4% | -0.8% |
| 2014 | 37.8% | 0.4% |
| 2013 | 32.8% | -4.7% |
| 2012 | 20.4% | 4.2% |
| 2011 | 10.2% | 15.7% |
| 2010 | 9.0% | -5.6% |
| 2009 | 8.8% | -19.0% |
| 2008 | -17.4% | 45.5% |
| 2007 | 2.1% | -0.3% |
| 2006 | 12.3% | 13.8% |
| 2005 | 1.0% | 23.3% |
| 2004 | 16.8% | 4.5% |
| 2003 | 14.5% | -37.9% |
| 2002 | -22.1% | 56.8% |
| 2001 | -12.1% | 10.2% |
| 2000 | 41.9% | -60.9% |
| 1999 | 1.3% | -6.1% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare Gross Profitability Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Gross Profitability signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.